When Brian J. Druker was a boy, he wanted to be a baseball player; Nicholas B. Lydon had his sights set on flying jets; Charles L. Sawyers knew early on that he wanted to practice medicine. Decades later, this trio (Figure 1) would collaborate to revolutionize the treatment of chronic myelogenous leukemia (CML). On September 14, the Albert and Mary Lasker Foundation announced that they will recognize these researchers with the 2009 Lasker-DeBakey Clinical Medical Research Award for research that led to the development of drugs, including imatinib (Gleevec) and dasatinib (Sprycel), which have converted CML from a fatal cancer to a manageable condition. Notably, imatinib was the first successful, molecularly targeted, small-molecule drug approved for cancer therapy. The winners spoke with the JCI about their success story.
Brooke Grindlinger
Usage data is cumulative from December 2023 through December 2024.
Usage | JCI | PMC |
---|---|---|
Text version | 466 | 54 |
152 | 12 | |
Figure | 67 | 1 |
Citation downloads | 60 | 0 |
Totals | 745 | 67 |
Total Views | 812 |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.